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First European
Case of Serotype A
MATa Cryptococcus
neoformans
Infection 
To the Editor: Cryptococcus neo-
formans is an opportunistic fungus
that causes meningoencephalitis, pri-
marily in immunocompromised
patients. However, C. neoformans can
also cause illness in apparently nor-
mal hosts. The yeast is a heterothallic
basidiomycete with two mating types,
MATa and MATα identified in all the
four serotypes, A, B, C, and D.
However, the mating type a of
serotype A is a rare and recent finding.
One strain was isolated from a
Tanzanian AIDS patient and a second
from the Italian environment; the first
was mating defective (1,2). We report
the isolation of a serotype A MATa
strain of clinical origin that was char-
acterized by mating at high frequency
under standard laboratory conditions.
In August 1998, a 45-year-old
Hungarian man was admitted to the
Laszlo Hospital for Infectious
Diseases in Budapest because of sep-
tic fever. The patient had a history of
hematologic malignancy (Hodgkin
disease), which was diagnosed in
1991. He had received several courses
of chemotherapy and radiation. After
4 years when his cancer was in remis-
sion, in September 1995, the disease
recurred (stage IVa) for which he
received several more courses of
chemotherapy, according to protocols
BEAM (carmustine, etoposide,
cytarabine, melphalan) and CEP
(lomustine, etoposide, prednimus-
tine). In February 1998, another
relapse was diagnosed and the patient
was given chemotherapy, according to
protocol COPP (cyclophosphamide,
vincristine, prednisolone, procar-
bazine) four times. In April 1998, he
was hospitalized with herpes zoster
infection and treated with acyclovir.
At the last admission, in August 1998,
he was pancytopenic and had septic
fever. Salmonella enteritidis was cul-
tured from his blood. The salmonella
septicemia was successfully treated
with ceftriaxone. As palliative treat-
ment, he received 4x10 mg vinblas-
tine for his residual disease. On
September 30, he became febrile
again. Cryptococcus neoformans was
isolated from his blood, although
cerebrospinal fluid culture and sero-
logic tests were negative. On the right
fossa cubitalis, cellulitis and a tender
mass were present, although he did
not have a history of recent central
line or cytostatic treatment on this
side. Cryptococcus neoformans was
isolated from the sample taken from
the mass. Antifungal treatment was
started with 600 mg fluconazole per
day and continued with amphotericin
B, 1 mg/kg/day. The patient died 6
weeks after the isolation of
Cryptococcus, probably because of
his uncontrolled Hodgkin disease. As
far as the physician was aware, the
patient had not visited other countries.
The strain, isolated from the
patient’s blood during the European
Confederation of Medical Mycology
Cryptococcosis Survey, was sent for
typing to the European Convenor. The
isolate, IUM 99-3617, was identified
as serotype A using Crypto Check
serotyping kit from Iatron Laboratories
(Tokyo, Japan) and genotyped as VN6
by multiplex polymerase chain reac-
tion (PCR) (3) by using the primers
previously described (4,5). The fungus
was shown to be haploid by cytofluori-
metric analysis (6). The strain’s fertili-
ty was investigated, according to
Kwon-Chung (7), by crossing the iso-
late with reference serotype A strains
H99 (MATα) and IUM 96-2828
(MATa), and with serotype D congenic
strains JEC20 (MATa) and JEC21
(MATα). When cocultured with MATα
strains (H99 and JEC21), IUM 99-
3617 produced abundant basidio-
spores. On the contrary, the strain did
not mate with JEC20 (MATa D) or
with IUM 96-2828 (MATa A).
The genotypic and phenotypic
characteristics of the fungus were
then compared with those of serotype
A (MATa and MATα) reference
strains. The mating type was analyzed
by using PCR amplification of MFa,
MFα genes, and STE20a- and
STE20α-specific genes for serotype A
and serotype D. PCR reaction was
performed as previously reported (4).
The amplification product showed
that IUM 99-3617, like IUM 96-2828,
contains only serotype A STE20a and
MFa genes.
To further confirm that IUM 99-
3617 was MATa in mating type, MFa
and STE 20a genes were sequenced
by an ABI PRISM 310 automatic
sequencer using Big Dye Terminator
(Applied Biosystems, Monza, Italy)
and the primers, forward and reverse
strands previously reported (4). The
sequences were then aligned with the
reported sequences of IUM 96-2828
(2,8), the Tanzanian isolate 295.1 (1),
H 99, and the congenic JEC 20 and
JEC 21 strains. The IUM 99-3617
sequences were found to be identical
to those of IUM 96-2828 and of the
Tanzanian isolate 295.1. The MFaA
and the STE20aA sequence of IUM
99-3617 have been submitted to
GenBank database (available from
URL: www.ncbi.nlm. gov/Bankit/
nhpbankit.cgi) under accession num-
ber AY182035 and AY182036,
respectively.
Virulence studies in the mouse
model demonstrate that, like IUM 96-
2828, the strain is significantly less
virulent than H99. The latter strain
caused 100% deaths day 29, while
IUM 99-3617 took until day 60 to kill
60% of mice (unpub. data). No differ-
ence was observed among the three
serotype A strains when virulence fac-
tors such as capsule, melanin, phos-
pholipase activity, and ability to grow
at 37°C were tested.
The MATa of C. neoformans
serotype A was long regarded as
extinct or as existing in an undiscov-
ered ecologic niche until the recent
finding of the clinical and the environ-
mental isolate (1,2). The existence of
MATa in nature is also supported by
recent studies designed to established
the origin of the serotype AD strains
(4,5). These studies demonstrated that
AD strains were diploid or aneuploid
hybrids derived from a fusion of
serotype A and D parents and that sev-
eral of them were harboring a
serotype A MATa locus. These hybrid
strains have been found fairly often in
Europe (9,10).
The finding of this isolate provides
evidence of the pathogenic role of this
rare mating type, emphasizes the crit-
ical function of molecular genetic
tools in the characterization of C. neo-
formans populations, and represents
an advance in knowledge of this fun-
gal species whose genome is undergo-
ing identification by a worldwide
research team. 
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Severe Acute
Respiratory
Syndrome:
Relapse? Hospital
Infection? 
To the Editor: Severe acute respi-
ratory syndrome (SARS) is an emerg-
ing infectious disease worldwide, and
relapsing SARS is a major concern.
We encountered a 60-year-old woman
who was admitted to the Princess
Margaret Hospital in Hong Kong on
March 29, 2003, with a fever of 39°C,
chills, cough, malaise, and sore throat
for 2 days before admission. She had
no history of travel within 2 weeks of
admission. She also had no close con-
tact with patients who had a diagnosis
of suspected or confirmed SARS.
Chest radiograph on admission indi-
cated consolidation over the right
middle zone. In accordance with the
diagnostic criteria proposed by the
World Health Organization (WHO),
this patient’s condition was diagnosed
as SARS in view of her symptoms,
temperature, and chest radiograph
findings (1).
Standard microbiologic investiga-
tions to exclude common respiratory
virus and bacterium for community-
acquired pneumonia, including
Mycobacterium tuberculosis, were
negative in our patient. Reverse tran-
scriptase–polymerase chain reaction
(RT-PCR) of nasopharyngeal aspirate
samples was negative for coronavirus
twice. The coronavirus antibody titer
was less than 1/25. The patient was
initially treated with oral clar-
ithromycin (500 mg twice a day) and
intravenous amoxycillin-clavulanate
combination (1.2 g three times a day).
Despite the negative evidence for
coronavirus infection, she was treated
with intravenous ribavirin (24 mg/kg
once a day) and hydrocortisone (10
mg/kg once a day) after 48 hours of
antibiotics therapy (2). The patient’s
symptoms were relieved, and she
remained afebrile 3 days after admis-
sion. Tolerance for medication was
good except for a moderate degree of
hemolytic anemia (her hemoglobin
level dropped to 9.1 g/dL) and
hypokalemia that developed during
treatment. On day 15, the chest radi-
ography was clear. The patient was
discharged after 3 weeks of hospital
stay. 
The patient attended outpatient
clinic on day 35, complaining of exer-
tional dyspnea, low-grade fever, and
malaise since her discharge. Her chest
radiography showed extensive shad-
owing. Computer tomographic scan
of the thorax indicated widespread
ground-glass shadowing in both lung
fields, which was especially promi-
nent at left lower and lingular lobes.
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